Clinical Trials

Betrnet stem cells and the origins of Barrett's esophagus

This project is designed to identify biologically based and clinically useful biomarkers that indicate tissue at risk of neoplastic progression and a patient's response to ablation therapy. The results of this study may lead to improved risk stratification in Barrett's esophagus and better targeting of resources for patients who are candidates for ablative therapy. This study will also provide key information about the origins of Barrett's esophagus and how the disease responds to treatment. View clinical trial.

Biomarkers in phototherapy of Barrett's esophagus

This study is being done to find out if the presence of certain biomarkers, which are abnormalities in molecules of cells, before and after treatment with radiofrequency ablation or photodynamic therapy may predict the effectiveness of treatment.

Effect of ablation therapy on Barrett's esophagus

This study is being conducted to assess the effect of ablation therapy on Barrett's esophagus. Ablation therapy, a Food and Drug Administration-approved treatment to decrease cancer risk in Barrett's esophagus mucosa, is being performed in the Barrett's Esophagus Unit on a regular basis.

However, the long-term outcomes of this therapy are not established, and there are patients who have been treated who later redevelop Barrett's mucosa. This study will allow for the storage of tissue samples that can later be used to assess the effect of ablative therapy on Barrett's esophagus. View clinical trial.

Endoscopic mucosal resection in Barrett's esophagus

This study is being done to evaluate the predictors of complications, including stricture formation, bleeding or perforation, associated with endoscopic mucosal resection for Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma. View clinical trial.

High-resolution optical imaging of Barrett's esophagus using Nvision volumetric laser endomicroscopy

This study will evaluate the performance of this device for visualizing the tissue of the esophagus. The standard way to see the inside of the esophagus is with a device called an endoscope, which is a thin, flexible plastic tube with a lens (like on a camera) on the end.

The Food and Drug Administration has approved both the endoscope system and the use of the device that will be used during the procedure in this study. It is called a volumetric laser endomicroscopy (VLE) catheter. Catheters are long, thin, flexible plastic tubes used to put something into the body. The new VLE catheter uses light waves to make very detailed images of the inside of the esophagus.

In this study, researchers would like to find out if VLE is able to make more-detailed pictures than the standard devices. If this is the case, VLE could be an effective, safe and cheaper way to test for Barrett's esophagus and diagnose cancer of the esophagus. View clinical trial.

Metformin hydrochloride in preventing esophageal cancer in patients with Barrett's esophagus

This study is being done to compare the percentage change in the mean pS6K1 immunostaining from baseline in mucosal Barrett's esophagus biopsies among patients assigned to 2,000 milligrams metformin hydrochloride once daily versus placebo, as determined from Barrett's mucosal biopsy samples obtained pre- and post-intervention. View clinical trial.